Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 15/20 | 0.63 |
| ▸ | DRD3 | P35462 | 14/20 | 0.63 |
| ▸ | DRD4 | P21917 | 3/20 | 0.56 |
| ▸ | DRD5 | P21918 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19358663 | 0.84 | DRD2 (0.67) | DRD2DRD3DRD4 | |
| SCHEMBL22303331 | 0.81 | DRD2 (0.79) | DRD2DRD3DRD4DRD5SLC6A4 | |
| SCHEMBL22302843 | 0.80 | DRD2 (0.77) | DRD2DRD3DRD4DRD5SLC6A4 | |
| SCHEMBL30579536 | 0.80 | DRD2 (0.77) | DRD2DRD3DRD4DRD5SLC6A4 | |
| SCHEMBL22302295 | 0.80 | DRD2 (0.69) | DRD2DRD3DRD4DRD5SLC6A2 | |
| SCHEMBL18073600 | 0.80 | DRD2 (0.77) | DRD2DRD3DRD4DRD5SLC6A4 | |
| SCHEMBL14494936 | 0.79 | DRD2 (0.74) | DRD2DRD3DRD4DRD5SLC6A2 | |
| SCHEMBL1898756 | 0.79 | ALDH1A1 (0.60) | DRD2DRD3SLC6A4 | |
| SCHEMBL23330962 | 0.78 | DRD2 (0.79) | DRD2DRD3DRD4DRD5SLC6A2 | |
| SCHEMBL22302317 | 0.78 | DRD2 (0.79) | DRD2DRD3DRD4DRD5SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140296249-A1 | 4-PHENYLPIPERAZINE DERIVATIVES WITH FUNCTIONALIZED LINKERS AS DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-10-02 | — | — | US | disclosed |
| US-8748608-B2 | 4-phenylpiperazine derivatives with functionalized linkers as dopamine D3 receptor selective ligands and methods of use | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-06-10 | — | — | US | disclosed |
| US-20100267737-A1 | 4-PHENYLPIPERAZINE DERIVATIVES WITH FUNCTIONALIZED LINKERS AS DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND METHODS OF USE | THE GOV. OF THE U.S.A AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH AND HUMAN SERVICES | 2010-10-21 | — | — | US | disclosed |
| WO-2008153573-A1 | 4-PHENYLPIPERAZINE DERIVATIVES WITH FUNCTIONALIZED LINKERS AS DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND METHODS OF USE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267737-A1 | 4-PHENYLPIPERAZINE DERIVATIVES WITH FUNCTIONALIZED LINKERS AS DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND METHODS OF USE | DRD3, DRD2, HTR3C | DRD2 2/4885DRD3 1/4885DRD4 4/4885 |
| US-20140296249-A1 | 4-PHENYLPIPERAZINE DERIVATIVES WITH FUNCTIONALIZED LINKERS AS DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND METHODS OF USE | DRD3, DRD2, SLC6A3 | DRD2 2/4885DRD3 1/4885DRD4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.